BMEA Biomea Fusion, Inc.
USHealthcareAs of 2026-07-10 14:52
Why BMEA matters now
Biomea Fusion, Inc. (BMEA) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.30 with -0.76% on the session and $77.3M in market capitalization; recent performance reads 1-month -3.28% and YTD -4.84%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-12.4M, and EPS of $-0.17. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -80.1%.
The latest indexable market news headline is "Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study" from Globe News Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $19.00; recent insider activity includes Averill Julianne filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.56
P/S
0.00
EV/EBITDA
-0.58
DCF Value
$0.98
FCF Yield
-80.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-196.7%
ROA
-96.9%
ROIC
-173.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-12.4M | $-0.17 |
| Q4 2025 | $0.00 | $4.6M | $0.06 |
| FY 2025 | $0.00 | $-61.8M | $-1.18 |
| Q3 2025 | $0.00 | $-16.4M | $-0.27 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$20.20
Target (Median)
$19.00
Target Range
$10.00 - $40.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.33
Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covalent inhibitor of menin, engineered for oral administration. Menin plays a crucial role as a transcriptional regulator in the abnormal signaling pathways found across numerous cancer types. Established in 2017, Biomea Fusion's operations are headquartered in Redwood City, California.